Physician profile
Freddy Malpartida
NPI 1417391178
$2,075.88
in general payments reported to CMS, 2019-2025
17 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.85 · 2020: $81.81 · 2021: $267 · 2022: $501 · 2023: $322 · 2024: $339 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.97 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $320.66 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $306.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.14 | 2021-2025 | Farxiga |
| Amgen INC. | $212.59 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $139.94 | 2020-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $128.17 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $125.55 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $117.78 | 2020-2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $82.46 | 2024-2025 | Ozempic, Wegovy |
| Travere Therapeutics, INC. | $75.79 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $58.57 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $53.85 | 2019 | |
| Fresenius USA Marketing, INC. | $50.91 | 2023-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $33.53 | 2021 | |
| Vifor Pharma, INC. | $30.56 | 2025 | Veltassa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $23.20 | 2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $16.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freddy Malpartida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.